Investors

SCYNEXIS to Present Process for Resolving Trace Impurities During AAPS

Print page


SCYNEXIS to Present Process for Resolving Trace Impurities During AAPS

CHICAGO [October 15, 2012] – Drug discovery company SCYNEXIS, Inc. will present a seminar on the company’s expertise in the rapid identification of trace levels of impurities in drug development during the 2012 annual meeting of the American Association of Pharmaceutical Scientists (AAPS) in Chicago.

Entitled Trace Impurity Resolution: Rapid Automated Isolation and Unambiguous Structure Elucidation, the seminar will be Oct. 16 during the AAPS conference at McCormick Place. The presentation will be from 1:30-3 p.m. in Seminar Room W 471A.

The issue of trace impurities encountered during development of compounds can be a serious problem and quickly hinder the development process if regulatory concerns are raised. Without an ability to quickly identify the impurity and track the root cause, companies can encounter significant delays and development cost overruns.

SCYNEXIS provides proprietary purification technology and integrated analytical and synthetic experience to isolate the trace impurity in high purity and elucidate its structure through NMR and MS. The company’s Integrated Pharmaceutical Solutions experts can re-synthesize the impurity for unambiguous structural confirmation, qualify the material as a reference standard and determine the relative response factor of the impurity in comparison to the API. All of this can be delivered rapidly allowing the client’s development program to move forward.

“When it comes to impurity resolution, what we’re providing at the end of the day is not just the structure of the impurity – through analytical, synthetic and regularity understanding, we can help our client determine the root cause of these unqualified impurities,” said Clare Murray, business development director for SCYNEXIS Integrated Pharmaceutical Solutions. “We provide high-value data for a complete CMC package, which saves time and mitigates downstream regulatory complications for our clients.”

Also visit the SCYNEXIS team at the AAPS meeting at Booth 1839.

About SCYNEXIS
SCYNEXIS delivers innovative solutions to solve the toughest problems in drug discovery and development for our pharmaceutical, global health and life science partners. We have integrated offerings of high-end chemistry and biology services with a focus on Discovery Research, Integrated Parasitology and Integrated Pharmaceutical Solutions. We have successfully delivered preclinical and clinical drug candidates to our customers across all major therapeutic indications and have developed our own proprietary cyclophilin inhibitor programs for the treatment of a broad range of diseases, including HCV and inflammation. www.scynexis.com.

SCYNEXIS Media Contacts:
Rick Rountree
Rick Rountree Communications, Inc.
rick@rickrountree.com
Tel. +1 919-878-1144

Alissa Maupin
SCYNEXIS
Marketing & Communications Manager
alissa.maupin@scynexis.com
Tel. +1 919-206-7246